AZ 628 Chemical Properties

Density 

1.21±0.1 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

DMSO: soluble10mg/mL, clear

form 

powder

pka

12.92±0.70(Predicted)

color 

white to beige

InChI

1S/C27H25N5O2/c1-17-8-9-21(31-25(33)18-6-5-7-19(12-18)27(2,3)15-28)14-24(17)30-20-10-11-23-22(13-20)26(34)32(4)16-29-23/h5-14,16,30H,1-4H3,(H,31,33)

InChIKey

ZGBGPEDJXCYQPH-UHFFFAOYSA-N

SMILES

[n]1([c](c2c(nc1)ccc(c2)Nc3c(ccc(c3)NC(=O)c4cc(ccc4)C(C)(C)C#N)C)=O)C

Safety Information

Hazard Codes 

T

Risk Statements 

25-36/37/38

Safety Statements 

26-36/37/39-45

RIDADR 

UN 2811 6.1 / PGIII

WGK Germany 

3

HS Code 

2922500090

Storage Class

6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects

Hazard Classifications

Acute Tox. 3 Oral
Eye Irrit. 2
Skin Irrit. 2
STOT SE 3

AZ 628 Usage And Synthesis

Uses

AZ 628 is an inhibitor of B-RAF and B-RAF(V600E)

Definition

ChEBI: 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxo-6-quinazolinyl)amino]phenyl]benzamide is a member of benzamides.

Biological Activity

az628 is a potent and newly discorvered inhibitor of braf, c-raf-1 and brafv600e with ic50 values of 105 nm, 29 nm and 34 nm, respectively. this compound prevents craf activation through persistently occupying the atp-binding site of raf kinase. specificity profile suggests that az628 also inhibits activation of other tyrosine protein kinases such as ddr2, vegfr2, lyn, flt1, fms and others.raf kinases a family of three serine/threonine-specific protein kinases and participate in the ras-raf-mek-erk signal transduction cascade, also known as the mitogen-activated protein kinase (mapk) cascade. the activation of mapk signaling leads to different cellular response such as cell proliferation, apoptosis and inflammation.az628 has the potent anti-tumor activity. in human colon and melanoma-derived cell line that carries the recurrent v600e activating braf mutation, az628 was shown to inhibit anchorage-dependent and -independent growth, induce cell cycle arrest, and cause apoptosis [1]. az628 may be antiangiogenic due to inhibition of vegfr2 [2].generation of melanoma cell line clones is obtained resistance to the raf kinase inhibitor az628. resistance to az628 is connected with raised levels of the raf downstream effector p-erk1/2. erk1/2 initiation in az628-resistant clones is interceded by mek. supported multiplication of az628-resistant clones is to a great extent autonomous of braf kinase action. az628-resistant clones express elevated craf. survival of az628-safe cells is subject to craf [1].

in vitro

AZ628 inhibits B-Raf, B-Raf AZ628 acts on B-Raf-containing M14 parental cell lines treated with increasing concentrations of AZ628, an effective inhibition of p-ERK1/2 levels was observed. It acts on AZ628-resistant M14 cells and does not inhibit ERK activation. AZ628 acts on NRAS-mutated malignant melanoma cells and effectively reduces ERK activation.

target

storage

Store at +4°C

References

1. montagut c, sharma sv, shioda t, mcdermott u, ulman m, ulkus le, et al. elevated craf as a potential mechanism of acquired resistance to braf inhibition in melanoma. cancer res 2008,68:4853-4861.2. khazak v, astsaturov i, serebriiskii ig, golemis ea. selective raf inhibition in cancer therapy. expert opin ther targets 2007,11:1587-1609.

AZ 628(878739-06-1)Related Product Information

• PLX4032
• Selumetinib
• TAK-632
• Tozasertib
• Trametinib
• GDC-0879